A phase II study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration- resistant prostate cancer (CRPC): A PCCTC trial
Publication
, Conference
Antonarakis, ES; Heath, EI; Posadas, EM; Harrison, MR; Bruce, JY; Yu, EY; Cho, SY; Wilding, GE; Fetterly, GJ; Hangauer, DG; Kwan, M-FR ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
May 20, 2012
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2012
Volume
30
Issue
15
Location
Chicago, IL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Antonarakis, E. S., Heath, E. I., Posadas, E. M., Harrison, M. R., Bruce, J. Y., Yu, E. Y., … Carducci, M. A. (2012). A phase II study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration- resistant prostate cancer (CRPC): A PCCTC trial. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 30). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
Antonarakis, Emmanuel S., Elisabeth I. Heath, Edwin M. Posadas, Michael Roger Harrison, Justine Yang Bruce, Evan Y. Yu, Steve Y. Cho, et al. “A phase II study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration- resistant prostate cancer (CRPC): A PCCTC trial.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
Antonarakis ES, Heath EI, Posadas EM, Harrison MR, Bruce JY, Yu EY, et al. A phase II study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration- resistant prostate cancer (CRPC): A PCCTC trial. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2012.
Antonarakis, Emmanuel S., et al. “A phase II study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration- resistant prostate cancer (CRPC): A PCCTC trial.” JOURNAL OF CLINICAL ONCOLOGY, vol. 30, no. 15, AMER SOC CLINICAL ONCOLOGY, 2012.
Antonarakis ES, Heath EI, Posadas EM, Harrison MR, Bruce JY, Yu EY, Cho SY, Wilding GE, Fetterly GJ, Hangauer DG, Kwan M-FR, Dyster LM, Carducci MA. A phase II study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration- resistant prostate cancer (CRPC): A PCCTC trial. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2012.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2012
Volume
30
Issue
15
Location
Chicago, IL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences